--(www.USEquityNews.com)-- 06/02/2008 - Healthcare industry alert provided by U.S. Equity News. TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, recently announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered as a therapy for the treatment of cancer, in this case, Melanoma. The article, in advance online publication 3 April 2008, titled, "Restoration of the Expression of Transporters Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity," is yet another promising research study that confirms and corroborates the TAP incorporated vaccine. There is now a vast amount of research data supporting and corroborating the initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition. For more information, please visit www.stocksjournal.com.
Seattle Genetics, Inc. (NASDAQ: SGEN) announced today that its collaborator, Genentech, Inc., has initiated a phase Ib clinical trial of SGN-40 in combination with Velcade(R) (bortezomib) for patients with relapsed or refractory multiple myeloma. This is the sixth ongoing clinical trial to evaluate SGN-40 either as a single agent or in combination with standard therapies for non-Hodgkin lymphoma and multiple myeloma. "Recent approvals of new multiple myeloma therapies, including Velcade, have extended median survival for patients, yet it remains an incurable disease," said Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics. "This trial is designed to evaluate the safety, tolerability and preliminary activity of the combination of SGN-40 and Velcade, towards the goal of identifying a therapeutic regimen that addresses the significant unmet medical need for these patients."
American Oriental Bioengineering (NYSE: AOB) today announced that its Board of Directors has authorized a share repurchase program for the repurchase of up to $75 million of the Company's outstanding common stock. Purchases under this program may be made, from time to time, in the open market, privately negotiated transactions, and accelerated stock repurchase transactions or otherwise, as determined by American Oriental Bioengineering and will be funded from available working capital. The number of shares to be purchased and the timing of purchases will be based on several factors, including the price of American Oriental Bioengineering's stock, general business and market conditions and other investment opportunities.
Abraxis BioScience, Inc. (NASDAQ: ABII), a fully integrated, global biotechnology company, today announced the presentation of results from an ongoing single-arm, open-label, Phase II clinical trial evaluating solvent-free ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound) in combination with trastuzumab and carboplatin for the first-line treatment of patients with HER2-positive metastatic breast cancer. The preliminary analysis showed that weekly ABRAXANE (ABI-007 or nab-paclitaxel) (100 mg/m2 three weeks on treatment, one week off) followed by carboplatin (AUC of 6 every four weeks) plus trastuzumab (4 mg/kg loading dose followed by 2 mg/kg on subsequent visits) demonstrated a 53 percent overall response rate and median progression free survival of nearly 16 months.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
